Cargando…
SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildt...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699342/ https://www.ncbi.nlm.nih.gov/pubmed/33228017 http://dx.doi.org/10.3390/biom10111573 |
_version_ | 1783616027013152768 |
---|---|
author | Balzer, Michael S. Rong, Song Nordlohne, Johannes Zemtsovski, Jan D. Schmidt, Sonja Stapel, Britta Bartosova, Maria von Vietinghoff, Sibylle Haller, Hermann Schmitt, Claus P. Shushakova, Nelli |
author_facet | Balzer, Michael S. Rong, Song Nordlohne, Johannes Zemtsovski, Jan D. Schmidt, Sonja Stapel, Britta Bartosova, Maria von Vietinghoff, Sibylle Haller, Hermann Schmitt, Claus P. Shushakova, Nelli |
author_sort | Balzer, Michael S. |
collection | PubMed |
description | Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildtype C57Bl/6N mice were treated with high-glucose dialysate via an intraperitoneal catheter, with or without addition of selective SGLT2 inhibitor dapagliflozin. PM structural changes, ultrafiltration capacity, and peritoneal equilibration testing (PET) status for glucose, urea, and creatinine were analyzed. Expression of SGLT and facilitative glucose transporters (GLUT) was analyzed by real-time PCR, immunofluorescence, and immunohistochemistry. Peritoneal effluents were analyzed for cellular and cytokine composition. We found that peritoneal SGLT2 was expressed in mesothelial cells and in skeletal muscle. Dapagliflozin significantly reduced effluent transforming growth factor (TGF-β) concentrations, peritoneal thickening, and fibrosis, as well as microvessel density, resulting in improved ultrafiltration, despite the fact that it did not affect development of high-glucose transporter status. In vitro, dapagliflozin reduced monocyte chemoattractant protein-1 release under high-glucose conditions in human and murine peritoneal mesothelial cells. Proinflammatory cytokine release in macrophages was reduced only when cultured in high-glucose conditions with an additional inflammatory stimulus. In summary, dapagliflozin improved structural and functional peritoneal health in the context of high-glucose PD. |
format | Online Article Text |
id | pubmed-7699342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76993422020-11-29 SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate Balzer, Michael S. Rong, Song Nordlohne, Johannes Zemtsovski, Jan D. Schmidt, Sonja Stapel, Britta Bartosova, Maria von Vietinghoff, Sibylle Haller, Hermann Schmitt, Claus P. Shushakova, Nelli Biomolecules Article Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildtype C57Bl/6N mice were treated with high-glucose dialysate via an intraperitoneal catheter, with or without addition of selective SGLT2 inhibitor dapagliflozin. PM structural changes, ultrafiltration capacity, and peritoneal equilibration testing (PET) status for glucose, urea, and creatinine were analyzed. Expression of SGLT and facilitative glucose transporters (GLUT) was analyzed by real-time PCR, immunofluorescence, and immunohistochemistry. Peritoneal effluents were analyzed for cellular and cytokine composition. We found that peritoneal SGLT2 was expressed in mesothelial cells and in skeletal muscle. Dapagliflozin significantly reduced effluent transforming growth factor (TGF-β) concentrations, peritoneal thickening, and fibrosis, as well as microvessel density, resulting in improved ultrafiltration, despite the fact that it did not affect development of high-glucose transporter status. In vitro, dapagliflozin reduced monocyte chemoattractant protein-1 release under high-glucose conditions in human and murine peritoneal mesothelial cells. Proinflammatory cytokine release in macrophages was reduced only when cultured in high-glucose conditions with an additional inflammatory stimulus. In summary, dapagliflozin improved structural and functional peritoneal health in the context of high-glucose PD. MDPI 2020-11-19 /pmc/articles/PMC7699342/ /pubmed/33228017 http://dx.doi.org/10.3390/biom10111573 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Balzer, Michael S. Rong, Song Nordlohne, Johannes Zemtsovski, Jan D. Schmidt, Sonja Stapel, Britta Bartosova, Maria von Vietinghoff, Sibylle Haller, Hermann Schmitt, Claus P. Shushakova, Nelli SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate |
title | SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate |
title_full | SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate |
title_fullStr | SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate |
title_full_unstemmed | SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate |
title_short | SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate |
title_sort | sglt2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699342/ https://www.ncbi.nlm.nih.gov/pubmed/33228017 http://dx.doi.org/10.3390/biom10111573 |
work_keys_str_mv | AT balzermichaels sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT rongsong sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT nordlohnejohannes sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT zemtsovskijand sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT schmidtsonja sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT stapelbritta sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT bartosovamaria sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT vonvietinghoffsibylle sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT hallerhermann sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT schmittclausp sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate AT shushakovanelli sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate |